湖南南新制药股份有限公司2025年第一次临时股东大会决议公告

Group 1 - The company held its first extraordinary general meeting of shareholders on October 10, 2025, in Guangzhou, China [2] - The meeting was presided over by the chairman, Mr. Zhang Shixi, and utilized a combination of on-site and online voting methods [2][3] - All current directors and supervisors attended the meeting, confirming full participation [3] Group 2 - A key resolution to cancel the supervisory board and amend the company's articles of association was passed with over two-thirds of the voting rights in favor [4][5] - The meeting's procedures and voting results were confirmed to be in compliance with relevant laws and regulations by the witnessing law firm [6] Group 3 - The company announced a share repurchase plan on April 28, 2025, with a budget between RMB 10 million and RMB 20 million, aiming to repurchase shares for employee stock ownership plans [9] - As of September 30, 2025, the company had repurchased 265,516 shares, representing 0.10% of the total share capital, at prices ranging from RMB 7.02 to RMB 7.86 per share, totaling approximately RMB 1.97 million [10] - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations [12]